Description:

SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DEA67F10-B6B9-1C53-E034-0003BA12F5E7

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00127205 Off Treatment - SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307) - 2287059v3.0

No Instruction available.

  1. StudyEvent: SOUTHWEST ONCOLOGY GROUPSUPPLEMENTARY OFF TREATMENT NOTICE (S0307)
    1. No Instruction available.
Header
Bone Scan
Did the patient have a bone scan after completion or discontinuation of protocol therapy?
Bone metastases?
Patient Preference
If oral and intravenous bisphosphonates are equally effective in preventing breast cancer recurrence in the bone, which would the patient prefer to receive?
Comments

Similar models